PRESENTATION

Q2 2023 — Presentation

Q2 2023PDF · 33 pages641 KB
DANAHER CORPORATION
Second Quarter 2023 Earnings Release
July 25, 2023

-- 1 of 33 --

2
Forward Looking Statements
Statements in this presentation that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking"
statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those
suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, potential future,
adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic , the impact of our debt obligations on our operations and liquidity, deterioration of or
instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address
foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new
markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other
regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health
care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the
businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships
and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or
violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax
audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production
capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and availability of the supplies we use
(including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the
impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations
relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal,
compliance, social and business factors (including the impact of the military conflict between Russia and Ukraine), disruptions relating to man-made and natural disasters, pension plan and healthcare costs,
inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is
available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2023. These forward-looking statements speak only as of the date of
this presentation (July 25, 2023) and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of
new information, future events and developments or otherwise.
With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation or in
the “Investors” section of Danaher’s web site, www.danaher.com, under the heading “Financial Reports” and subheading “Quarterly Earnings.” In addition, in addressing various financial metrics the
presentation describes certain of the more significant factors that impacted year-over-year performance. For additional factors that impacted year-over-year performance, please refer to our earnings release
and the other related presentation materials supplementing today’s call, all of which are available in the “Investors” section of Danaher’s web site under the heading “Financial Reports” and subheading
“Quarterly Earnings,” as well as our Annual Report on Form 10-K for the year ended December 31, 2022. All references in this presentation (1) to financial metrics relate only to the continuing operations of
Danaher’s business, unless otherwise noted; and (2) to “growth” or other period-to-period changes refer to year-over-year comparisons unless otherwise indicated. We may also describe certain products
and devices which have applications submitted and pending for certain regulatory approvals.

-- 2 of 33 --

Second Quarter 2023 Performance Summary
$7,751 $7,157
Q2 2022 	Q2 2023
$2.76
$2.05
Q2 2022 	Q2 2023
-25.7% -7.5%
Core -7.0%
FX -0.5%
Throughout this presentation, with respect to revenue performance, for the definitions of "Acquisitions," “Core,” and “FX,” please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of
Danaher's website.
($ millions)
ADJUSTED DILUTED NET
EARNINGS PER COMMON SHARE
REVENUE

-- 3 of 33 --

Second Quarter 2023 Performance Summary
28.4%
20.0%
Q2 2022 	Q2 2023
-840 BPS
Core -730 bps
Acquisitions -10 bps
Other -100 bps
Throughout this presentation when referred to in connection with operating profit margins, “Acquisitions” refers to the impact of businesses owned for less than one year or disposed of during such period and not treated as discontinued operations,“Other” refers to the impact of impairment and
charges incurred in 2023, net of impairment and other charges incurred in 2022 and costs incurred related to preparation for the anticipated separation of the Company's Environmental and Applied Solutions business incurred in 2023; for further description of these items, please refer to the
accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.
OPERATING PROFIT MARGIN
$1,711
$1,589
Q2 2022 	Q2 2023
-7.0%
FREE CASH FLOW PERFORMANCE
($ millions)

-- 4 of 33 --

Second Quarter 2023: Biotechnology
$2,266 $1,885
Q2 2022 	Q2 2023
36.4%
25.5%
Q2 2022 	Q2 2023
5
-17.0%
Core -16.5%
FX -0.5%
Core -850 bps
Acquisitions -20 bps
Other -220 bps
-1,090 BPS
($ millions)
REVENUE OPERATING PROFIT MARGIN
Life Sciences

-- 5 of 33 --

Second Quarter 2023: Life Sciences
20.6% 18.9%
Q2 2022 	Q2 2023
$1,701 	$1,796
Q2 2022 	Q2 2023
6
+5.5%
Core +5.5%
Acquisitions +1.0%
FX -1.0%
Core -140 bps
Acquisitions -30 bps
-170 BPS
($ millions)
OPERATING PROFIT MARGIN	REVENUE
Industrial

-- 6 of 33 --

Second Quarter 2023: Diagnostics
31.2%
19.0%
Q2 2022 	Q2 2023
$2,561 $2,231
Q2 2022 	Q2 2023
7
-13.0%
Core -11.5%
FX -1.5%
Core -1,220 bps
-1,220 BPS
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 7 of 33 --

Second Quarter 2023: Environmental &
Applied Solutions
25.1% 	24.3%
Q2 2022 	Q2 2023
$1,223 	$1,245
Q2 2022 	Q2 2023
8
+2.0%
Core +1.5%
Acquisitions +0.5%
Core -115 bps
Acquisitions +10 bps
Other +25 bps
-80 BPS
($ millions)
OPERATING PROFIT MARGIN	REVENUE

-- 8 of 33 --

9
GUIDANCE

-- 9 of 33 --

Q & A
10

-- 10 of 33 --



-- 11 of 33 --

DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
AND SUPPLEMENTAL FORWARD-LOOKING INFORMATION
THREE AND SIX-MONTH PERIODS ENDED JUNE 30, 2023 AND JULY 1, 2022

-- 12 of 33 --

TABLE OF CONTENTS
Page
1 Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales Growth (Decline) by Segment
2 Forecasted Core Sales (Decline) Growth, Base Business Core Sales Growth and Adjusted Operating Profit Margin
3 Segment Sales, Operating Profit and Adjusted Operating Profit
4 Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
8 Other Non-GAAP Adjusted P&L Measures
14 Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
15 Operating Profit Margins and Year-Over-Year Core Operating Margin Changes
16 Cash Flow, Free Cash Flow, Operating Cash Flow to Net Earnings Ratio and Free Cash Flow to Net Earnings Conversion Ratio
17 Statement Regarding Non-GAAP Measures
19 Supplemental Forward-Looking Information and Quarter Highlights
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements
within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated
by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, potential future, adverse impacts on our business,
results of operations and financial condition related to the COVID-19 pandemic, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we
serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates
and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees,
agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the
results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate
acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other
benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past
and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to
grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to
multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our
production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product
liability and recalls, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our
channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory
measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing
diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of the military conflict between Russia and Ukraine), disruptions
relating to man-made and natural disasters, pension plan and healthcare costs, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual
results to differ materially from these forward-looking statements is available in our SEC filings, including our 2022 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of
2023. These forward-looking statements speak only as of the date of this document (July 24, 2023) and except to the extent required by applicable law, the Company does not assume any obligation to update or
revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

-- 13 of 33 --

% Change Three-Month Period Ended June 30, 2023 vs. Comparable 2022 Period
Segments
Total Company Biotechnology Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales (decline) growth (GAAP) (7.5) % (17.0) % 5.5 % (13.0) % 2.0 %
Impact of:
Acquisitions/divestitures — % — % (1.0) % — % (0.5) %
Currency exchange rates 0.5 % 0.5 % 1.0 % 1.5 % — %
Core sales (decline) growth (non-GAAP) (7.0) % (16.5) % 5.5 % (11.5) % 1.5 %
Impact of COVID-19 related testing, vaccines and therapeutics 9.0 % +High-single
digit +Low-single
digit +Double-digit — %
Base business core sales growth (decline) (non-GAAP) 2.0 % -High-single
digit +High-single
digit +High-single
digit 1.5 %
% Change Six-Month Period Ended June 30, 2023 vs. Comparable 2022 Period
Segments
Total Company Biotechnology Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales (decline) growth (GAAP) (7.0) % (16.5) % 4.0 % (11.5) % 3.5 %
Impact of:
Acquisitions/divestitures — % — % (1.0) % — % (0.5) %
Currency exchange rates 1.5 % 2.0 % 2.0 % 2.0 % 1.0 %
Core sales (decline) growth (non-GAAP) (5.5) % (14.5) % 5.0 % (9.5) % 4.0 %
Impact of COVID-19 related testing, vaccines and therapeutics 9.5 % +Low-double
digit +Low-single
digit +Double-digit — %
Base business core sales growth (decline) (non-GAAP) 4.0 % -Mid-single
digit +High-single
digit +Low-double
digit 4.0 %
Note: We expect overall demand for the Company’s COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We believe certain demand
for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future pandemics) and COVID-19 testing
will continue, though that demand will likely be uncertain and will vary from period to period. At the beginning of 2022, the Company believed that on a relative basis, the level of ongoing
demand for products supporting COVID-19 testing would be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and
therapeutics, due in part to expected COVID-19 case levels, vaccination rates and use of therapies. However, as a result of lower vaccination rates and the spread of less severe variants of
the virus, 2022 demand for the Company’s products supporting COVID-19 related vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the year.
Therefore, beginning with the first quarter of 2023, we have revised the definition of “base business core sales growth” on a basis that not only excludes revenues related to COVID-19
testing but also excludes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this adjusted definition of “base business core sales growth” provides
more useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that
otherwise may be obscured by fluctuations in demand for COVID-19 related products.
DANAHER CORPORATION
Sales (Decline) Growth by Segment, Core Sales (Decline) Growth by Segment and Base Business Core Sales Growth (Decline) by Segment
1

-- 14 of 33 --

The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as currency
translation, acquisitions and divested product lines. Additionally, we do not reconcile adjusted operating profit margin (or components thereof) to the comparable GAAP
measures because of the difficulty in estimating the other unknown components such as investment gains and losses, impairments and separation costs, which would be
reflected in any forecasted GAAP operating profit.
% Change Three-Month
Period Ending September
29, 2023 vs. Comparable
2022 Period
% Change Year Ending
December 31, 2023 vs.
Comparable 2022 Period
Core sales decline (non-GAAP) -Low-teens to mid-
teens -High-single digit to
low-double digit
Impact of COVID-19 related testing, vaccines and therapeutics +Low-double digit +Low-double digit
Base business core sales (decline) growth (non-GAAP) -Low-single digit +Low-single digit
Three-Month Period
Ending September 29, 2023 Year Ending
December 31, 2023
Adjusted operating profit margin (non-GAAP) ~26.0% ~29.0%
DANAHER CORPORATION
Forecasted Core Sales (Decline) Growth, Base Business Core Sales Growth and Adjusted Operating Profit Margin
2

-- 15 of 33 --

Sales (GAAP)
Biotechnology $ 1,885 $ 2,266 $ 3,749 $ 4,482
Life Sciences 1,796 1,701 3,505 3,367
Diagnostics 2,231 2,561 4,607 5,205
Environmental & Applied Solutions 1,245 1,223 2,463 2,385
Total Company $ 7,157 $ 7,751 $ 14,324 $ 15,439
Operating Profit (GAAP)
Biotechnology $ 480 $ 824 $ 1,076 $ 1,624
Life Sciences 340 350 661 668
Diagnostics 424 800 1,101 1,686
Environmental & Applied Solutions 302 307 601 543
Other (117) (76) (216) (144)
Total Company $ 1,429 $ 2,205 $ 3,223 $ 4,377
Amortization of Intangible Assets (GAAP)
Biotechnology $ 218 $ 205 $ 435 $ 419
Life Sciences 104 105 209 212
Diagnostics 50 50 100 101
Environmental & Applied Solutions 12 13 24 27
Total Company $ 384 $ 373 $ 768 $ 759
Other Operating Profit Adjustments 1
Biotechnology $ 42 $ — $ 42 $ 14
Life Sciences — — — 24
Diagnostics — — — 3
Environmental & Applied Solutions 6 9 6 10
Other 37 — 65 1
Total Company $ 85 $ 9 $ 113 $ 52
Adjusted Operating Profit (non-GAAP) 2
Biotechnology $ 740 $ 1,029 $ 1,553 $ 2,057
Life Sciences 444 455 870 904
Diagnostics 474 850 1,201 1,790
Environmental & Applied Solutions 320 329 631 580
Other (80) (76) (151) (143)
Total Company $ 1,898 $ 2,587 $ 4,104 $ 5,188
Three-Month Period Ended Six-Month Period Ended
June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
2 Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined).
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit
($ in millions)
3

-- 16 of 33 --

Three-Month Period Ended June 30, 2023
Biotechnology Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 1,106
Interest, Net 8
Other Nonoperating (Income) Expense 29
Income Taxes 286
Operating Profit (GAAP) $ 480 $ 340 $ 424 $ 302 $ (117) $ 1,429
Other Operating Profit Adjustments 1 42 — — 6 37 85
Depreciation 39 32 96 10 1 178
Amortization of Intangible Assets 218 104 50 12 — 384
Adjusted EBITDA (Non-GAAP) $ 779 $ 476 $ 570 $ 330 $ (79) $ 2,076
Interest, Net (8)
Other Nonoperating Income (Expense) (29)
Income Taxes (286)
Other Operating Profit Adjustments 1 (85)
Depreciation (178)
Amortization of Intangible Assets (384)
Net Earnings (GAAP) $ 1,106
Sales (GAAP) $ 1,885 $ 1,796 $ 2,231 $ 1,245 $ 7,157
Net Earnings Margin (GAAP) 15.5 %
Operating Profit Margin (GAAP) 25.5 % 18.9 % 19.0 % 24.3 % 20.0 %
Adjusted EBITDA Margin (Non-GAAP) 3 41.3 % 26.5 % 25.5 % 26.5 % 29.0 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
($ in millions)
4

-- 17 of 33 --

Three-Month Period Ended July 1, 2022
Biotechnology Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 1,680
Interest, Net 49
Other Nonoperating (Income) Expense 87
Income Taxes 389
Operating Profit (GAAP) $ 824 $ 350 $ 800 $ 307 $ (76) $ 2,205
Other Operating Profit Adjustments 1 — — — 9 — 9
Depreciation 43 27 98 10 1 179
Amortization of Intangible Assets 205 105 50 13 — 373
Adjusted EBITDA (Non-GAAP) $ 1,072 $ 482 $ 948 $ 339 $ (75) $ 2,766
Interest, Net (49)
Other Nonoperating Income (Expense) (87)
Income Taxes (389)
Other Operating Profit Adjustments 1 (9)
Depreciation (179)
Amortization of Intangible Assets (373)
Net Earnings (GAAP) $ 1,680
Sales (GAAP) $ 2,266 $ 1,701 $ 2,561 $ 1,223 $ 7,751
Net Earnings Margin (GAAP) 21.7 %
Operating Profit Margin (GAAP) 36.4 % 20.6 % 31.2 % 25.1 % 28.4 %
Adjusted EBITDA Margin (Non-GAAP) 3 47.3 % 28.3 % 37.0 % 27.7 % 35.7 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
($ in millions)
5

-- 18 of 33 --

Six-Month Period Ended June 30, 2023
Biotechnology Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 2,556
Interest, Net 28
Other Nonoperating (Income) Expense 5
Income Taxes 634
Operating Profit (GAAP) $ 1,076 $ 661 $ 1,101 $ 601 $ (216) $ 3,223
Other Operating Profit Adjustments 1 42 — — 6 65 113
Depreciation 79 61 189 20 2 351
Amortization of Intangible Assets 435 209 100 24 — 768
Adjusted EBITDA (Non-GAAP) $ 1,632 $ 931 $ 1,390 $ 651 $ (149) $ 4,455
Interest, Net (28)
Other Nonoperating Income (Expense) (5)
Income Taxes (634)
Other Operating Profit Adjustments 1 (113)
Depreciation (351)
Amortization of Intangible Assets (768)
Net Earnings (GAAP) $ 2,556
Sales (GAAP) $ 3,749 $ 3,505 $ 4,607 $ 2,463 $ 14,324
Net Earnings Margin (GAAP) 17.8 %
Operating Profit Margin (GAAP) 28.7 % 18.9 % 23.9 % 24.4 % 22.5 %
Adjusted EBITDA Margin (Non-GAAP) 3 43.5 % 26.6 % 30.2 % 26.4 % 31.1 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
($ in millions)
6

-- 19 of 33 --

Six-Month Period Ended July 1, 2022
Biotechnology Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings (GAAP) $ 3,405
Interest, Net 102
Other Nonoperating (Income) Expense 107
Income Taxes 763
Operating Profit (GAAP) $ 1,624 $ 668 $ 1,686 $ 543 $ (144) $ 4,377
Other Operating Profit Adjustments 1 14 24 3 10 1 52
Depreciation 87 55 192 21 3 358
Amortization of Intangible Assets 419 212 101 27 — 759
Adjusted EBITDA (Non-GAAP) $ 2,144 $ 959 $ 1,982 $ 601 $ (140) $ 5,546
Interest, Net (102)
Other Nonoperating Income (Expense) (107)
Income Taxes (763)
Other Operating Profit Adjustments 1 (52)
Depreciation (358)
Amortization of Intangible Assets (759)
Net Earnings (GAAP) $ 3,405
Sales (GAAP) $ 4,482 $ 3,367 $ 5,205 $ 2,385 $ 15,439
Net Earnings Margin (GAAP) 22.1 %
Operating Profit Margin (GAAP) 36.2 % 19.8 % 32.4 % 22.8 % 28.4 %
Adjusted EBITDA Margin (Non-GAAP) 3 47.8 % 28.5 % 38.1 % 25.2 % 35.9 %
1 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Net Earnings, Operating Profit, Adjusted EBITDA, Net Earnings Margin, Operating Profit Margin and Adjusted EBITDA Margin
($ in millions)
7

-- 20 of 33 --

Three-Month Period Ended June 30, 2023
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before income
taxes Income taxes
Net earnings
for calculation
of diluted
earnings per
common share
Diluted net
earnings per
common
share 4
Reported (GAAP) $ 7,157 $ (3,116) 56.5 % $ 1,429 20.0 % $ 1,392 $ (286) $ 1,106 I $ 1.49
Amortization of acquisition-related
intangible assets A — — — 384 5.4 384 384 0.52
Fair value net (gains) losses on
investments B — — — — — 32 32 0.04
Separation costs C — — — 37 0.5 37 37 0.05
Impairments and other charges D — 14 0.2 48 0.7 48 48 0.06
Tax effect of the above adjustments F (95) (95) (0.13)
Discrete tax adjustments G 18 18 0.02
Rounding — — — — (0.1) — — — —
Adjusted (Non-GAAP) $ 7,157 $ (3,102) 56.7 % $ 1,898 26.5 % $ 1,893 $ (363) $ 1,530 $ 2.05
Three-Month Period Ended June 30, 2023
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 7,157 $ (2,194) (30.7) % $ (418) (5.8) % $ (29) $ (8)
Amortization of acquisition-related
intangible assets A — 384 5.4 — — — —
Fair value net (gains) losses on
investments B — — — — — 32 —
Separation costs C — 37 0.5 — — — —
Impairments and other charges D — 34 0.5 — — — —
Adjusted (Non-GAAP) $ 7,157 $ (1,739) (24.3) % $ (418) (5.8) % $ 3 $ (8)
4 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month period may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
8

-- 21 of 33 --

Three-Month Period Ended July 1, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before income
taxes Income taxes
Net earnings
for calculation
of diluted
earnings per
common share
Diluted net
earnings per
common
share 4
Reported (GAAP) $ 7,751 $ (3,030) 60.9 % $ 2,205 28.4 % $ 2,069 $ (389) $ 1,658 I $ 2.25
Amortization of acquisition-related
intangible assets A — — — 373 4.8 373 373 0.50
Fair value net (gains) losses on
investments B — — — — — 98 98 0.13
Impairments and other charges D — — — 9 0.1 9 9 0.01
Tax effect of the above adjustments F (98) (98) (0.13)
Discrete tax adjustments G (8) (8) (0.01)
MCPS "as if converted" H — — — — — — — 22 —
Rounding — — — — 0.1 — — — 0.01
Adjusted (Non-GAAP) $ 7,751 $ (3,030) 60.9 % $ 2,587 33.4 % $ 2,549 $ (495) $ 2,054 $ 2.76
Three-Month Period Ended July 1, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 7,751 $ (2,085) (26.9) % $ (431) (5.6) % $ (87) $ (49)
Amortization of acquisition-related
intangible assets A — 373 4.8 — — — —
Fair value net (gains) losses on
investments B — — — — — 98 —
Impairments and other charges D — 9 0.1 — — — —
Adjusted (Non-GAAP) $ 7,751 $ (1,703) (22.0) % $ (431) (5.6) % $ 11 $ (49)
4 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month period may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
9

-- 22 of 33 --

Six-Month Period Ended June 30, 2023
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before income
taxes Income taxes
Net earnings
for calculation
of diluted
earnings per
common share
Diluted net
earnings per
common
share 4
Reported (GAAP) $ 14,324 $ (5,913) 58.7 % $ 3,223 22.5 % $ 3,190 $ (634) $ 2,535 I $ 3.42
Amortization of acquisition-related
intangible assets A — — — 768 5.4 768 768 1.03
Fair value net (gains) losses on
investments B — — — — — 10 10 0.01
Separation costs C — — — 65 0.5 65 65 0.09
Impairments and other charges D — 14 0.1 48 0.3 48 48 0.06
Tax effect of the above adjustments F (167) (167) (0.22)
Discrete tax adjustments G 13 13 0.02
MCPS "as if converted" H — — — — — — — 21 —
Rounding — — — — — — — — 0.01
Adjusted (Non-GAAP) $ 14,324 $ (5,899) 58.8 % $ 4,104 28.7 % $ 4,081 $ (788) $ 3,293 $ 4.42
Six-Month Period Ended June 30, 2023
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 14,324 $ (4,341) (30.3) % $ (847) (5.9) % $ (5) $ (28)
Amortization of acquisition-related
intangible assets A — 768 5.4 — — — —
Fair value net (gains) losses on
investments B — — — — — 10 —
Separation costs C — 65 0.5 — — — —
Impairments and other charges D — 34 0.2 — — — —
Rounding — — (0.1) — — — —
Adjusted (Non-GAAP) $ 14,324 $ (3,474) (24.3) % $ (847) (5.9) % $ 5 $ (28)
4 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month period may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
10

-- 23 of 33 --

Six-Month Period Ended July 1, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
before income
taxes Income taxes
Net earnings
for calculation
of diluted
earnings per
common share
Diluted net
earnings per
common
share 4
Reported (GAAP) $ 15,439 $ (6,013) 61.1 % $ 4,377 28.4 % $ 4,168 $ (763) $ 3,362 I $ 4.56
Amortization of acquisition-related
intangible assets A — — — 759 4.9 759 759 1.02
Fair value net (gains) losses on
investments B — — — — — 122 122 0.16
Impairments and other charges D — 18 0.1 52 0.3 52 52 0.07
Loss on partial settlement of a defined
benefit plan E — — — — — 10 10 0.01
Tax effect of the above adjustments F (183) (183) (0.24)
Discrete tax adjustments G (49) (49) (0.07)
MCPS "as if converted" H — — — — — — — 43 —
Rounding — — — — — — — — 0.01
Adjusted (Non-GAAP) $ 15,439 $ (5,995) 61.2 % $ 5,188 33.6 % $ 5,111 $ (995) $ 4,116 $ 5.52
Six-Month Period Ended July 1, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 15,439 $ (4,177) (27.1) % $ (872) (5.6) % $ (107) $ (102)
Amortization of acquisition-related
intangible assets A — 759 4.9 — — — —
Fair value net (gains) losses on
investments B — — — — — 122 —
Impairments and other charges D — 34 0.2 — — — —
Loss on partial settlement of a defined
benefit plan E — — — — — 10 —
Rounding — — 0.1 — — — —
Adjusted (Non-GAAP) $ 15,439 $ (3,384) (21.9) % $ (872) (5.6) % $ 25 $ (102)
4 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month period may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
11

-- 24 of 33 --

A Amortization of acquisition-related intangible assets in the following historical periods (only the pretax amounts set forth below are reflected in the amortization
line item above):
Three-Month Period Ended Six-Month Period Ended
June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022
Pretax $ 384 $ 373 $ 768 $ 759
After-tax 310 300 620 611
B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods (only the pretax amounts set forth
below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended Six-Month Period Ended
June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022
Pretax $ 32 $ 98 $ 10 $ 122
After-tax 25 75 8 93
C Costs incurred in the three and six-month periods ended June 30, 2023, related to preparation for the anticipated separation of the Company’s Environmental &
Applied Solutions business, primarily related to professional fees for legal, tax, finance and information technology services and duplicative general and
administrative costs ($37 million and $65 million pretax as reported in this line item, and $34 million and $59 million after-tax, respectively).
D Impairment charges related to technology, a facility and other assets in the Biotechnology segment and customer relationships in the Environmental & Applied
Solutions segment recorded in the three and six-month periods ended June 30, 2023 ($48 million pretax as reported in this line item, $37 million after-tax).
Impairment charges related to technology and customer relationships in the Environmental & Applied Solutions segment recorded in both the three and six-
month periods ended July 1, 2022 ($9 million pretax as reported in this line item, $7 million after-tax). In the six-month period ended July 1, 2022, additional
charges incurred primarily related to impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia ($43 million
pretax as reported in this line item, $40 million after-tax).
E Loss on a partial settlement of a defined benefit plan as a result of the transfer of a portion of the Company’s non-U.S. pension liabilities related to one defined
benefit plan to a third-party in the six-month period ended July 1, 2022 ($10 million pretax as reported in this line item, $9 million after-tax,).
F This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application
of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS
dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
G Discrete tax adjustments and other tax-related adjustments for the three-month period ended June 30, 2023, include the impact of a net discrete tax loss of $18
million related primarily to tax costs related to the planned separation of the Environmental & Applied Solutions business, tax costs related to legal and
operational actions taken to realign certain businesses and changes in estimates associated with prior period uncertain tax positions, partially offset by interest on
prior year tax refunds. Discrete tax adjustments and other tax-related adjustments for the six-month period ended June 30, 2023, include the impact of a net
discrete tax loss of $13 million related primarily to tax costs related to the planned separation of the Environmental & Applied Solutions business, tax costs
related to legal and operational actions taken to realign certain businesses and changes in estimates associated with prior period uncertain tax positions, partially
offset by excess tax benefits from stock-based compensation and interest on prior year tax refunds. Discrete tax adjustments and other tax-related adjustments for
the three-month period ended July 1, 2022, include the impact of net discrete tax benefits of $8 million related primarily to changes in estimates associated with
prior period uncertain tax positions and excess tax benefits from stock-based compensation. Discrete tax adjustments and other tax-related adjustments for the
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
12

-- 25 of 33 --

six-month period ended July 1, 2022, include the impact of net discrete tax benefits of $49 million related primarily to excess tax benefits from stock-based
compensation and changes in estimates associated with prior period uncertain tax positions.
H In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72 billion
in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A and Series B were payable on a cumulative basis at an annual rate
of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Each share of MCPS Series A converted on April 15, 2022 into 6.6632
shares of Danaher’s common stock. Each share of MCPS Series B converted on April 17, 2023 into 5.0175 shares of Danaher’s common stock. For the
calculation of net earnings per common share, the impact of the dilutive MCPS is calculated under the “if-converted” method and the related MCPS dividends are
excluded. For the purposes of calculating adjusted earnings per common share, the Company has excluded the paid MCPS cash dividends and assumed the “if-
converted” method of share dilution (the incremental shares of common stock deemed outstanding applying the “if-converted” method of calculating share
dilution only with respect to any MCPS the conversion of which would be dilutive in the particular period are referred to as the “Converted Shares”) for any
MCPS that were anti-dilutive for the given period. For additional information about the impact of the MCPS on the calculation of diluted EPS, see note 5 in the
Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding table below.
I Net earnings for calculation of diluted earnings per common share is summarized as follows:
Three-Month Period Ended Six-Month Period Ended
June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022
Net earnings $ 1,106 $ 1,680 $ 2,556 $ 3,405
MCPS dividends — (22) (21) (63)
Net earnings attributable to common stockholders for Basic EPS 1,106 1,658 2,535 3,342
Adjustment for MCPS dividends for dilutive MCPS — — — 20
Net earnings attributable to common stockholders after assumed conversions for Diluted
EPS $ 1,106 $ 1,658 $ 2,535 $ 3,362
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
13

-- 26 of 33 --

Forecasted
Three-Month Period Ended Six-Month Period Ended
Three-Month
Period Ending
September 29,
2023
Year Ending
December 31,
2023	June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022
Average common stock and common equivalent shares
outstanding - diluted (GAAP) 5 744.7 736.0 740.2 736.8 746.9 744.1
Converted shares 6 — 8.6 5.1 8.6 — 2.5
Adjusted average common stock and common equivalent shares
outstanding - diluted (non-GAAP) 744.7 744.6 745.3 745.4 746.9 746.6
5 The impact of the MCPS Series B calculated under the if-converted method was dilutive for the three-month period ended June 30, 2023, and as such 1.5 million shares underlying the
MCPS Series B were included in the calculation of diluted EPS in the three-month period. The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for
the six-month period ended June 30, 2023 and the three and six-month periods ended July 1, 2022, and as such 5.1 million shares for the six-month period ended June 30, 2023 and 8.6
million for both the three and six-month periods ended July 1, 2022 underlying the MCPS Series B were excluded from the calculation of diluted EPS and the related MCPS Series B
dividends of $21 million for the six-month period ended June 30, 2023 and $22 million and $43 million for the three and six-month periods ended July 1, 2022, respectively, were included
in the calculation of net earnings for diluted EPS. There were no MCPS Series B dividends declared in the second quarter of 2023 prior to their conversion. As of April 17, 2023, all
outstanding shares of the MCPS Series B converted into 8.6 million shares of the Company’s common stock.
The impact of the MCPS Series A calculated under the if-converted method was dilutive for both the three and six-month periods ended July 1, 2022, and as such 1.1 million and 6.0
million shares, respectively, underlying the MCPS Series A were included in the calculation of diluted EPS. The related MCPS Series A dividends of $20 million for the six-month period
ended July 1, 2022 were excluded from the calculation of net earnings for diluted EPS. On April 15, 2022, all outstanding shares of the MCPS Series A converted into 11.0 million shares
of the Company’s common stock. There were no MCPS Series A dividends declared in the second quarter of 2022 prior to their conversion.
Additionally, for the year ending December 31, 2023, the impact of the MCPS Series B calculated under the if-converted method is forecasted to be anti-dilutive and as such,
approximately 2.5 million shares underlying the MCPS Series B are excluded from the calculation of diluted EPS.
6 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using the actual
conversion rates as of June 30, 2023 and an average 20 trading-day trailing Volume Weighted Average Price of $250.49 as of July 1, 2022.
DANAHER CORPORATION
Average and Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
14

-- 27 of 33 --

Segments
Total Company Biotechnology Life Sciences Diagnostics
Environmental
& Applied
Solutions
Three-Month Period Ended July 1, 2022 Operating Profit Margins (GAAP) 28.40 % 36.40 % 20.60 % 31.20 % 25.10 %
Second quarter 2023 impact from operating profit margins of businesses that
have been owned for less than one year (0.10) (0.20) (0.30) — 0.10
Second quarter 2023 impairment charges related to technology, a facility and
other assets in the Biotechnology segment and customer relationships in the
Environmental & Applied Solutions segment, net of a second quarter 2022
impairment charge related to technology and customer relationships in the
Environmental & Applied Solutions segment (0.50) (2.20) — — 0.25
Second quarter 2023 costs incurred related to preparation for the anticipated
separation of the Company's Environmental & Applied Solutions business (0.50) — — — —
Year-over-year core operating profit margin changes for the second quarter
2023 (defined as all year-over-year operating profit margin changes other than
the changes identified in the line items above) (non-GAAP) (7.30) (8.50) (1.40) (12.20) (1.15)
Three-Month Period Ended June 30, 2023 Operating Profit Margins (GAAP) 20.00 % 25.50 % 18.90 % 19.00 % 24.30 %
Segments
Total Company Biotechnology Life Sciences Diagnostics
Environmental
& Applied
Solutions
Six-Month Period Ended July 1, 2022 Operating Profit Margins (GAAP) 28.40 % 36.20 % 19.80 % 32.40 % 22.80 %
First half of 2023 impact from operating profit margins of businesses that have
been owned for less than one year or were disposed of during such period and
did not qualify as discontinued operations (0.15) (0.20) (0.35) — 0.10
Second quarter 2023 impairment charges related to technology, a facility and
other assets in the Biotechnology segment and customer relationships in the
Environmental & Applied Solutions segments, net of a second quarter 2022
impairment charge related to technology and customer relationships in the
Environmental & Applied Solutions segment (0.30) (1.10) — — 0.15
First half of 2023 costs incurred related to preparation for the anticipated
separation of the Company's Environmental & Applied Solutions business (0.45) — — — —
First half of 2022 impairments of accounts receivable and inventory as well as
accruals for contractual obligations in Russia 0.25 0.30 0.75 0.05 0.05
Year-over-year core operating profit margin changes for first half of 2023
(defined as all year-over-year operating profit margin changes other than the
changes identified in the line items above) (non-GAAP) (5.25) (6.50) (1.30) (8.55) 1.30
Six-Month Period Ended June 30, 2023 Operating Profit Margins (GAAP) 22.50 % 28.70 % 18.90 % 23.90 % 24.40 %
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it determines that such
costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Operating Profit Margins and Year-Over-Year Core Operating Margin Changes
15

-- 28 of 33 --

Three-Month Period Ended Year-over-Year
Change
Six-Month Period Ended Year-over-Year
Change	June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022
Total Cash Flow:
Net cash provided by operating activities (GAAP) $ 1,926 $ 2,000 $ 3,873 $ 3,968
Total cash used in investing activities (GAAP) $ (431) $ (400) $ (735) $ (903)
Total cash used in financing activities (GAAP) $ (208) $ (1,160) $ (470) $ (1,434)
Free Cash Flow:
Net cash provided by operating activities (GAAP) $ 1,926 $ 2,000 ~ (3.5) % $ 3,873 $ 3,968 ~ (2.5) %
Less: payments for additions to property, plant &
equipment (capital expenditures) (GAAP) (341) (296) (616) (546)
Plus: proceeds from sales of property, plant & equipment
(capital disposals) (GAAP) 4 7 4 9
Free cash flow (non-GAAP) $ 1,589 $ 1,711 ~ (7.0) % $ 3,261 $ 3,431 ~ (5.0) %
Operating Cash Flow to Net Earnings Ratio (GAAP)
Net cash provided by operating activities (GAAP) $ 1,926 $ 2,000 $ 3,873 $ 3,968
Net earnings (GAAP) 1,106 1,680 2,556 3,405
Operating cash flow to net earnings conversion ratio 1.74 1.19 1.52 1.17
Free Cash Flow to Net Earnings Conversion Ratio:
Free cash flow from above (non-GAAP) $ 1,589 $ 1,711 $ 3,261 $ 3,431
Net earnings (GAAP) 1,106 1,680 2,556 3,405
Free cash flow to net earnings conversion ratio (non-
GAAP) 1.44 1.02 1.28 1.01
We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment (“capital expenditures”) plus the proceeds from sales of plant, property and
equipment (“capital disposals”).
DANAHER CORPORATION
Cash Flow, Free Cash Flow, Operating Cash Flow to Net Earnings Ratio and Free Cash Flow to Net Earnings Conversion Ratio
($ in millions)
16

-- 29 of 33 --

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may
not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering
additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors:
• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior
and future periods and to our peers;
• with respect to core sales and related non-GAAP sales measures, identify underlying growth trends in our business and compare our sales performance with prior
and future periods and to our peers; and
• with respect to free cash flow and related non-GAAP cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash without external
financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of
free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures, and as a result the entire
free cash flow amount is not necessarily available for discretionary expenditures).
We expect overall demand for the Company’s COVID-19 related products to continue moderating as the pandemic has evolved toward endemic status. We believe
certain demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future
pandemics) and COVID-19 testing will continue, though that demand will likely be uncertain and will vary from period to period. At the beginning of 2022, the Company
believed that on a relative basis, the level of ongoing demand for products supporting COVID-19 testing would be subject to more fluctuations in demand than the level of
demand for products supporting COVID-19 related vaccines and therapeutics, due in part to expected COVID-19 case levels, vaccination rates and use of therapies.
However, as a result of lower vaccination rates and the spread of less severe variants of the virus, 2022 demand for the Company’s products supporting COVID-19 related
vaccines and therapeutics fluctuated and declined more than anticipated at the beginning of the year. Therefore, beginning with the first quarter of 2023, we have revised
the definition of “base business core sales growth” on a basis that not only excludes revenues related to COVID-19 testing but also excludes revenues from products that
support COVID-19 related vaccines and therapeutics. We believe this adjusted definition of “base business core sales growth” provides more useful information to
investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth trends in the Company’s business that otherwise
may be obscured by fluctuations in demand for COVID-19 related products.
Management uses the non-GAAP measures referenced above to measure the Company’s operating and financial performance, and uses core sales and non-GAAP
measures similar to Adjusted Diluted Net Earnings Per Common Share and the FCF Measure in the Company’s executive compensation program.
• The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
◦ Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges
are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition
activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related
amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense
facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive
and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales
generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully
amortized.
◦ Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic
nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from
application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of
our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more
consistent comparison of operating results over time.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
17

-- 30 of 33 --

◦ Other Adjustments: With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share, we exclude these items because
they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance
during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.
For example, we excluded the first quarter 2022 charge for asset impairments, accruals for contractual obligations and similar items related to our Russia
operations because, even though it is possible we could incur additional charges in the future, we do not believe these charges are indicative of
Danaher’s ongoing operating costs.
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”) Series
A converted into Danaher common stock on April 15, 2022 and the MCPS Series B mandatorily converted into Danaher common stock on the mandatory
conversion date of April 17, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of designations). With respect
to the calculation of Adjusted Diluted Net Earnings Per Common Share, we apply the “if converted” method of share dilution to the MCPS Series A and B in all
applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive in the period. We believe this presentation provides useful
information to investors by helping them understand what the net impact will be on Danaher’s earnings per share-related measures once the MCPS convert into
Danaher common stock.
• With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to "restructuring charges” and “other
adjustments”, we exclude the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations)
because the timing, size, number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and
make comparisons of long-term performance difficult.
• We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in the
applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps our investors
compare the profitability of our individual segments to peer companies with like business lines.
• With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to
volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number
and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business
trends and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate
the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
The Company provides forecasted sales only on a non-GAAP basis because of the difficulty in estimating the other components of GAAP revenue, such as currency
translation, acquisitions and divested product lines. Additionally, we do not reconcile adjusted operating profit margin (or components thereof) to the comparable GAAP
measures because of the difficulty in estimating the other unknown components such as investment gains and losses, impairments and separation costs, which would be
reflected in any forecasted GAAP operating profit.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
18

-- 31 of 33 --

Three-Month
Period Ending
September 29, 2023 Year Ending
December 31, 2023
COVID-19 testing sales ~$100 ~$1,200
COVID vaccine and therapeutics sales ~$150
Bioprocessing base business core revenue (decline) ~(10.0) %
Corporate expense 7 ~$(80) ~$(310)
Non-service components of periodic benefit costs (as included in Other income (expense), net in the Consolidated Condensed
Statements of Earnings) ~$2 ~$8
Interest expense, net 8 ~$(10) ~$(40)
Effective tax rate ~19.5 % ~19.5 %
7 Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management’s
evaluation of reportable segment operating performance, excluding costs related to preparation for the anticipated separation of the Company’s Environmental & Applied Solutions
business.
8 Interest expense, net is defined as interest expense net of interest income. This line item is an assumption rather than a forecast. The estimated interest expense, net is calculated assuming
the currency exchange rates in effect as of June 30, 2023 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding.
Quarter Highlights Bioprocessing
Q2 2023 Base Business Core Revenue Growth by Segment Current environment:
• Biotechnology -high-single digit
◦ Bioprocessing -high-single digit • Destocking continued as we moved through Q2
◦ Large pharma working through inventory they built
during the pandemic
◦ Emerging biotech still down as they conserve capital
• Life Sciences +high-single digit
◦ Life Sciences Instruments +mid-single digit
• Diagnostics +high-single digit
◦ Non-respiratory testing at Cepheid +>30%
◦ LBS +high-single digit and Beckman Diagnostics +mid-single digit
• In China, ongoing market correction accelerated as Q2
progressed
• Given these dynamics, we have begun to more actively work
with customers to manage down inventory levels	• Environmental & Applied Solutions +1.5%
◦ Water Quality +mid-single digit
◦ Product Identification -mid-single digit
DANAHER CORPORATION
Supplemental Forward-Looking Information and Quarter Highlights
($ in millions)
19

-- 32 of 33 --

20

-- 33 of 33 --